“三看”上市苏企答卷 亮点多干劲足信心强

Core Viewpoint - The performance of Jiangsu listed companies in 2024 shows a mixed picture, with total revenue reaching 3.45 trillion yuan, a slight increase of 0.4% year-on-year, while net profit decreased, indicating pressures but also resilience in operations [2][3]. Revenue and Profitability - Jiangsu listed companies achieved a total revenue of 3.45 trillion yuan in 2024, with a net profit of 238.12 billion yuan, reflecting a decline compared to the previous year [3]. - Over 60% of listed companies reported revenue growth, and nearly 80% were profitable, showcasing strong operational quality across various sectors [3]. Sector Highlights - Innovative pharmaceutical companies are entering a harvest phase, with Tai Zhou Ya Hong Pharmaceutical reporting a revenue of 202 million yuan, a staggering increase of 1365.55% year-on-year [3]. - Wuxi Di Zhe Pharmaceutical achieved a revenue of 360 million yuan, up 294.24%, driven by rapid commercialization [3]. Mechanical Equipment Sector - The mechanical equipment sector showed enhanced profitability, with over ten companies reporting net profit growth exceeding 100%, driven by energy-saving policies and strong demand [5]. - Yangdian Technology's net profit surged by 939.68%, highlighting the sector's robust performance [5]. Research and Development Investment - Jiangsu listed companies invested a total of 124.48 billion yuan in R&D in 2024, a 1.2% increase, with an average R&D expenditure of 180 million yuan [6]. - Over 200 companies reported having core technological capabilities, with R&D intensity reaching 3.6% overall and 7.4% for the Sci-Tech Innovation Board [6][7]. Mergers and Acquisitions - Mergers and acquisitions are becoming a key strategy for enhancing performance and competitiveness, with Jiangsu companies actively pursuing domestic and international acquisitions [9][10]. - Notable acquisitions include Longpan Technology's purchase of a battery company for approximately 100 million yuan and Nanwei Medical's acquisition of a 51% stake in a subsidiary for about 289 million yuan [9][10]. Cash Flow and Financial Health - The net cash flow from operating activities for Jiangsu listed companies reached 393.36 billion yuan, indicating strong financial health and the ability to support acquisitions [11].